Health TrialsbyHealthPanel

Preliminary Evaluation of Clinical Application of SPECT Imaging Targeting GPC3

ConditionsHCCSPECT-CT
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

About this trial

This project will target patients with highly clinically suspected or histopathology diagnosed hepatocellular carcinoma (HCC) using targeted GPC3-specific imaging agents (e.g. , Iodine-131-aGPC3-Scfv) for integrated SPECTCT imaging, to evaluate the pharmacokinetics distribution of the targeted drug in patients with hepatocellular carcinoma (HCC) by low-dose integrated diagnosis and treatment (i.e. , Iodine-131-RRB- imaging, to determine the metabolism, safety and tolerability of the drug in vivo Secondary objective: to evaluate the targeting of GPC3-SPECIFIC imaging agents in patients with hepatocellular carcinoma to assess the feasibility of this targeted agent for future treatment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

the subject or his/her legal representative can sign and date the informed consent form

commitment to follow the research procedures and cooperate in the implementation of the full-process research

patients with high clinical suspicion or histopathology diagnosis of HCC and generally in good condition

patients with a history of hepatocellular carcinoma who recur after treatment

Disqualifiers

inability to complete SPECTCT examination (including inability to lie down, claustrophobia, radiophobia, etc.)

acute systemic diseases and electrolyte disorders

patients with known hypersensitivity to GPC3 imaging agents or synthetic excipients

patients considered by the investigator to have poor adherence

Trial design

Design model

Single group

Treatments tested in this trial

  • 131I-aGPC3

    Drug

    Using targeted GPC3-specific imaging agents (e.g. , Iodine-131-aGPC3-Scfv) for integrated SPECTCT imaging, evaluate the pharmacokinetics distribution of the targeted drug in patients with hepatocellular carcinoma (HCC) by low-dose integrated diagnosis and treatment (i.e. , Iodine-131- imaging), and determine the metabolism, safety and tolerability of the drug in vivo

Treatment groups

6 Participants
are divided into 1 treatment group
Group A: sPECT imaging targeting GPC3 in malignant tumorsExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Radiation dose to human body

Metric/method of measurement：Use OLINDA/EXM software

Time frame
1 year

Secondary outcomes

1

Region of Interest,ROI

Time frame
1 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: